{"id":"emtricitabine-ftc-tenofovir-tdf","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Lactic acidosis (rare but serious)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Renal impairment (tenofovir-related)"},{"rate":null,"effect":"Bone density loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Emtricitabine and tenofovir are both nucleoside/nucleotide analogs that inhibit HIV reverse transcriptase, the enzyme the virus uses to convert its RNA genome into DNA for integration into host cells. By blocking this critical step in the HIV replication cycle, the combination reduces viral load and slows disease progression. This fixed-dose combination is commonly used as part of antiretroviral therapy regimens.","oneSentence":"This combination of two nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:24.724Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (as part of combination antiretroviral therapy)"},{"name":"HIV-1 pre-exposure prophylaxis (PrEP)"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":934,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"emtricitabine [FTC]/tenofovir [TDF]","genericName":"emtricitabine [FTC]/tenofovir [TDF]","companyName":"Tibotec, Inc","companyId":"tibotec-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of two nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection (as part of combination antiretroviral therapy), HIV-1 pre-exposure prophylaxis (PrEP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}